ClinicalTrials.gg
CompletedNCT03812029Updated May 6, 2023Results posted

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Vonafexor and Placebo in Non-alcoholic Steatohepatitis, sponsored by Enyo Pharma. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Enyo Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
135th of 460
120 · median 56
Started
2019
with 61 others
Phase 2
192 of 547
15 open now
Registered
273rd of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 135th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 273rd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effects of EYP001a (Vonafexor) with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH

Read the detailed description

This is a 2-part, randomized, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of Vonafexor in patients with NASH who likely have stage F2 to F3 fibrosis at approximately 50 global clinical sites. Overall, approximately 114 eligible patients will be enrolled: 24 patients in Part A (Safety Run-in Cohort), followed by 90 patients in Part B.

In Part A, 24 patients will be randomized on Day 1 to 1 of 4 parallel treatment groups: 100 mg Vonafexor twice daily (BID), 200 mg Vonafexor once daily (QD), 400 mg Vonafexor QD, or placebo BID. In Part B, 90 patients will be randomized on Day 1 to 1 of 3 parallel treatment groups: 100 mg Vonafexor QD, 200 mg Vonafexor QD, or placebo QD.

03

Conditions studied

  • Non-alcoholic Steatohepatitis

Keywords

  • EYP001 (vonafexor)
  • Liver Diseases
  • Non-alcoholic Fatty Liver Disease
  • Non-alcoholic Steatohepatitis
  • NASH
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Suspected diagnosis of NASH, evidenced by elevated (ALT), liver stiffness compatible with F2 or F3 fibrosis and Liver Fat Content (LFC) ≥10% as measured by MRI
  • Women of and male patients with female partners must agree to use a dual method of

Exclusion criteria

Exclusion Criteria:

  • Evidence of worsening liver injury
  • Previous diagnosis of other forms of non-NASH liver disease
  • Use of Vitamin E, glitazones, glucagon-like Peptide-1 receptor agonists, ursodeoxycholic acid, or obeticholic acid within 90 days prior to screening
  • History of cirrhosis or liver decompensation
  • Known history of alcohol abuse or daily heavy alcohol consumption
  • Pregnant or breastfeeding women
  • Type 1 diabetes mellitus and uncontrolled type 2 diabetes mellitus
  • Patients with to MRI imaging
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Vonafexor 100 mg BID

    Oral dose twice daily for 12 weeks (84 days)

    Drug: Vonafexor

  • Experimental
    Vonafexor 200 mg QD

    Oral dose once daily for 12 weeks (84 days)

    Drug: Vonafexor

  • Experimental
    Vonafexor 400 mg QD

    Oral dose once daily for 12 weeks (84 days)

    Drug: Vonafexor

  • Placebo comparator
    Placebo

    Oral dose twice daily for 12 weeks (84 days)

    Other: Placebo

  • Experimental
    Vonafexor 100 mg QD

    Oral dose once daily for 12 weeks (84 days)

    Drug: Vonafexor

Interventions

  • DrugVonafexor

    Oral tablets

  • OtherPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

    The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.

    Time frame: 12 weeks

Secondary outcomes

  1. Analysis of Change From Baseline in Glomerular Filtration rate_Part B

    Time frame: 12 weeks

  2. Analysis of Percent Change (Relative) From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

    The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.

    Time frame: 12 weeks

  3. Analysis of Change From Baseline in Corrected T1 (CT1)

    Time frame: 12 weeks

  4. Analysis of Change From Baseline in Alanine Aminotransferase (ALT)

    Time frame: 12 weeks

  5. Analysis of Change From Baseline in Gamma Glutamyltranspeptidase (GT)

    Time frame: 12 weeks

  6. Analysis of Change From Baseline in Body Weight

    Time frame: 12 weeks

  7. Analysis of Change From Baseline in Waist Circumference

    Time frame: 12 weeks

  8. Analysis of Change From Baseline in Waist to Hip ratio_Part B

    Time frame: 12 weeks

  9. Analysis of Change From Baseline in Glomerular Filtration rate_Part A

    For Part A, as per ICH, analysis were performed as defined in the SAP: data from the 3 vonafexor treatment groups were pooled and compared with the placebo group.

    Time frame: 12 weeks

07

Results

Posted May 6, 2023

Participant flow

Participant flow — Overall Study
MilestonePlacebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part B
Started717323133
Completed57322523
Not completed2100610
Withdrew: Protocol violation10010
Withdrew: Withdrawal by subject10022
Withdrew: Stopping rules01000
Withdrew: Adverse event09035
Withdrew: Lost to follow-up00003

Outcome measures

PrimaryAnalysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.

Time frame:
12 weeks
Reported as:
Least squares mean · Percentage of liver fat change
Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
Percentage of liver fat changePlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BPlacebo Part AVonafexor Pooled Part A
Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)-2.3 (-4.0 to -0.6)-6.3 (-8.1 to -4.5)-5.4 (-7.2 to -3.6)3.9 (-2.5 to 10.4)-4.7 (-8.5 to 0.9)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · ANCOVA · p = 0.0015 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · ANCOVA · p = 0.0121 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part A vs Vonafexor Pooled Part A · ANCOVA · p = 0.0371 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Glomerular Filtration rate_Part B
Time frame:
12 weeks
Reported as:
Least squares mean · mL/min/1.73m2
Analysis of Change From Baseline in Glomerular Filtration rate_Part B
mL/min/1.73m2Placebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part B
Analysis of Change From Baseline in Glomerular Filtration rate_Part B-2.7 (-6.6 to 1.2)6.2 (1.9 to 10.2)3.2 (-1.2 to 7.7)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · Mixed Models Analysis · p = 0.003 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · Mixed Models Analysis · p = 0.04 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Percent Change (Relative) From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.

Time frame:
12 weeks
Reported as:
Least squares mean · Percent change
Analysis of Percent Change (Relative) From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
Percent changePlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BPlacebo Part AVonafexor Pooled Part A
Analysis of Percent Change (Relative) From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)-10.5 (-19.0 to -2.0)-30.4 (-39.4 to -21.3)-25.3 (-34.3 to -16.2)11.7 (-28.5 to 51.9)-25.0 (-48.4 to -1.5)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · ANCOVA · p = 0.0017 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · ANCOVA · p = 0.018 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part A vs Vonafexor Pooled Part A · ANCOVA · p = 0.13 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Corrected T1 (CT1)
Time frame:
12 weeks
Reported as:
Least squares mean · msec
Analysis of Change From Baseline in Corrected T1 (CT1)
msecPlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BPlacebo Part AVonafexor Pooled Part A
Analysis of Change From Baseline in Corrected T1 (CT1)-9.9 (-38.5 to 18.7)-80.2 (-110.6 to -49.8)-71.8 (-100.4 to -43.2)35.0 (-27.0 to 97.0)-58.2 (-98.7 to -17.8)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · ANCOVA · p = 0.001 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · ANCOVA · p = 0.002 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part A vs Vonafexor Pooled Part A · ANCOVA · p = 0.018 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Alanine Aminotransferase (ALT)
Time frame:
12 weeks
Reported as:
Least squares mean · U/L
Analysis of Change From Baseline in Alanine Aminotransferase (ALT)
U/LPlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BPlacebo Part AVonafexor Pooled Part A
Analysis of Change From Baseline in Alanine Aminotransferase (ALT)-11.7 (-18.9 to -4.6)-16.3 (-24.1 to -8.4)-7.5 (-15.3 to 0.4)-4.1 (-27.5 to 19.3)17.7 (1.9 to 33.5)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · Mixed Models Analysis · p = 0.09 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · Mixed Models Analysis · p = 0.47 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part A vs Vonafexor Pooled Part A · Mixed Models Analysis · p = 0.14 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Gamma Glutamyltranspeptidase (GT)
Time frame:
12 weeks
Reported as:
Least squares mean · U/L
Analysis of Change From Baseline in Gamma Glutamyltranspeptidase (GT)
U/LPlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BPlacebo Part AVonafexor Pooled Part A
Analysis of Change From Baseline in Gamma Glutamyltranspeptidase (GT)-3.9 (-9.9 to 2.2)-40.6 (-47.1 to -34.0)-34.1 (-40.6 to -27.7)3.7 (-7.8 to 15.2)-25.2 (-34.2 to -16.3)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · Mixed Models Analysis · p = <0.0001 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · Mixed Models Analysis · p = <0.0001 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part A vs Vonafexor Pooled Part A · Mixed Models Analysis · p = 0.0002 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Body Weight
Time frame:
12 weeks
Reported as:
Least squares mean · kg
Analysis of Change From Baseline in Body Weight
kgPlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BPlacebo Part AVonafexor Pooled Part A
Analysis of Change From Baseline in Body Weight-0.1 (-1.0 to 0.9)-1.7 (-2.7 to -0.7)-2.5 (-3.5 to -1.5)1.2 (-1.0 to 3.4)-2.2 (-3.7 to -0.7)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · Mixed Models Analysis · p = 0.017 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · Mixed Models Analysis · p = 0.0006 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part A vs Vonafexor Pooled Part A · Mixed Models Analysis · p = 0.006 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Waist Circumference
Time frame:
12 weeks
Reported as:
Least squares mean · cm
Analysis of Change From Baseline in Waist Circumference
cmPlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BPlacebo Part AVonafexor Pooled Part A
Analysis of Change From Baseline in Waist Circumference0.1 (-1.2 to 1.3)-1.2 (-2.6 to 0.1)-2.2 (-3.6 to -0.9)-1.8 (-5.0 to 1.4)-2.9 (-5.0 to -0.7)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · Mixed Models Analysis · p = 0.16 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · Mixed Models Analysis · p = 0.01 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part A vs Vonafexor Pooled Part A · Mixed Models Analysis · p = 0.57 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Waist to Hip ratio_Part B
Time frame:
12 weeks
Reported as:
Median · ratio
Analysis of Change From Baseline in Waist to Hip ratio_Part B
ratioPlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part B
Analysis of Change From Baseline in Waist to Hip ratio_Part B0.014 (0.001 to 0.026)-0.017 (-0.031 to -0.003)-0.010 (-0.024 to 0.004)
Statistical analysis
  • Placebo Part B vs Vonafexor 100 mg QD Part B · Mixed Models Analysis · p = 0.0017 (a priori threshold for statistical significance : \<0.05.)
  • Placebo Part B vs Vonafexor 200 mg QD Part B · Mixed Models Analysis · p = 0.0093 (a priori threshold for statistical significance : \<0.05.)
SecondaryAnalysis of Change From Baseline in Glomerular Filtration rate_Part A

For Part A, as per ICH, analysis were performed as defined in the SAP: data from the 3 vonafexor treatment groups were pooled and compared with the placebo group.

Time frame:
12 weeks
Reported as:
Geometric mean · mL/min/1.73m^2
Analysis of Change From Baseline in Glomerular Filtration rate_Part A
mL/min/1.73m^2Placebo Part AVonafexor Pooled Part A
Analysis of Change From Baseline in Glomerular Filtration rate_Part A-4 ± 18.4-11.3 ± 12.5

Adverse events

Collected over After dose the first dose of study drug until D96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Part A0/7 (0%)0/7 (0%)4/7 (57.1%)
Vonafexor 100 mg BID Part A0/6 (0%)0/6 (0%)6/6 (100%)
Vonafexor 200 mg QD Part A0/5 (0%)0/5 (0%)4/5 (80%)
Vonafexor 400 mg QD Part A0/6 (0%)0/6 (0%)6/6 (100%)
Placebo Part B0/32 (0%)1/32 (3.1%)22/32 (68.8%)
Vonafexor 100 mg QD Part B0/31 (0%)1/31 (3.2%)25/31 (80.6%)
Vonafexor 200 mg QD Part B0/33 (0%)2/33 (6.1%)30/33 (90.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo Part AVonafexor 100 mg BID Part AVonafexor 200 mg QD Part AVonafexor 400 mg QD Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part B
Angina instableCardiac disorders0/70/60/50/60/321/310/33
Respiratory failureRespiratory, thoracic and mediastinal disorders0/70/60/50/60/321/310/33
VertigoEar and labyrinth disorders0/70/60/50/61/320/310/33
Transaminases increasedInvestigations0/70/60/50/60/320/311/33
COVID-19Infections and infestations0/70/60/50/60/320/311/33
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPlacebo Part AVonafexor 100 mg BID Part AVonafexor 200 mg QD Part AVonafexor 400 mg QD Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part B
PruritusSkin and subcutaneous tissue disorders0/75/64/56/64/3219/3122/33
NauseaGastrointestinal disorders0/70/60/52/62/320/315/33
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/70/61/50/60/320/310/33
Adverse drug reactionGeneral disorders0/70/61/50/60/320/310/33
AnxietyPsychiatric disorders0/70/61/50/60/320/310/33
Abdominal painGastrointestinal disorders0/70/61/50/60/320/311/33
Abdominal rigidityGastrointestinal disorders0/70/61/50/60/320/311/33
HyperhidrosisSkin and subcutaneous tissue disorders0/70/61/50/60/321/310/33
FatigueGeneral disorders1/71/60/50/61/320/310/33
AgitationPsychiatric disorders0/71/60/50/60/320/310/33

Baseline characteristics

For Part A, data from the 3 vonafexor treatment groups were pooled and summarized. Due to the small number of subjects by treatment group in Part A, and as the Study EYP001 202 Part A PK results between groups were found to be nonlinear with similar exposure for the vonafexor 200 mg QD and vonafexor 400 mg QD groups, only the pooled vonafexor treatment group were compared with the placebo group.

Age, Continuous
Age, Continuous(years)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
Age Part A48.7 ± 18.456.1 ± 8.9———54.0 ± 12.4
Age Part B——57.3 ± 10.358.1 ± 13.754.0 ± 11.956.4 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
Female21418142169
Male5314171251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
Hispanic or Latino25681031
Not Hispanic or Latino51226232389
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
American Indian or Alaska Native000011
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American013217
White716292631109
More than one race000000
Unknown or Not Reported000303
Height
Height(cm)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
Height Part A169.0 ± 7.4163.2 ± 9.9———164.9 ± 9.5
Height Part B——168.1 ± 9.8167.1 ± 8.5166.8 ± 10.1167.3 ± 9.4
Weight
Weight(kg)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
Weight Part A112.4 ± 32.6103.4 ± 25.4———106.0 ± 27.3
Weight Part B——97.5 ± 18.395.8 ± 14.098.8 ± 18.497.4 ± 16.9
BMI
BMI(kg/m^2)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
BMI Part A39.3 ± 10.238.8 ± 9.0———38.9 ± 9.1
BMI Part B——34.3 ± 4.334.3 ± 4.135.4 ± 5.134.7 ± 4.5
Waist circumference
Waist circumference(cm)Placebo Part AVonafexor Pooled Part APlacebo Part BVonafexor 100 mg QD Part BVonafexor 200 mg QD Part BTotal
Waist circumference Part A128.9 ± 31.5116.1 ± 16.0———119.8 ± 21.7
Waist circumference Part B——112.6 ± 13.0111.4 ± 8.6114.1 ± 11.8112.7 ± 11.3
08

Study locations

42 sites
  • ENYO PHARMA Investigative site 0424
    North Little Rock, Arkansas 72117, United States
  • ENYO PHARMA Investigative site 0418
    Lakewood Ranch, Florida 34211, United States
  • ENYO PHARMA Investigative site 0402
    Ocoee, Florida 34761, United States
  • ENYO PHARMA Investigative site 0420
    Orlando, Florida 32806, United States
  • ENYO PHARMA Investigative site 0419
    Port Orange, Florida 32127, United States
  • ENYO PHARMA Investigative site 0403
    Athens, Georgia 30607, United States
  • ENYO PHARMA Investigative site 0423
    Savannah, Georgia 31406, United States
  • ENYO PHARMA Investigative site 0407
    Snellville, Georgia 30078, United States
  • ENYO PHARMA Investigative site 0409
    Indianapolis, Indiana 46260, United States
  • ENYO PHARMA Investigative site 0413
    Baton Rouge, Louisiana 70809, United States
  • ENYO PHARMA Investigative site 0404
    Marrero, Louisiana 70072, United States
  • ENYO PHARMA Investigative site 0422
    Baltimore, Maryland 21202, United States
  • ENYO PHARMA Investigative site 0412
    Jackson, Mississippi 39216, United States
  • ENYO PHARMA Investigative site 0414
    Kansas City, Missouri 64131, United States
  • ENYO PHARMA Investigative site 0406
    Durham, North Carolina 27710, United States
  • ENYO PHARMA Investigative site 0411
    Columbus, Ohio 43213, United States
  • ENYO PHARMA Investigative site 0401
    Charleston, South Carolina 29401, United States
  • ENYO PHARMA Investigative site 0408
    Charleston, South Carolina 29407, United States
  • ENYO PHARMA Investigative site 0421
    Rapid City, South Dakota 57701, United States
  • ENYO PHARMA Investigative site 0405
    Arlington, Texas 76012, United States
  • ENYO PHARMA Investigative site 0416
    Austin, Texas 78746, United States
  • ENYO PHARMA Investigative site 0417
    Edinburg, Texas 78539, United States
  • ENYO PHARMA Investigative site 0410
    San Antonio, Texas 78215, United States
  • ENYO PHARMA Investigative site 0415
    San Antonio, Texas 78229, United States
  • ENYO PHARMA Investigative site 0105
    Brussels, 1070, Belgium
  • ENYO PHARMA Investigative site 0101
    Edegem, 2650, Belgium
  • ENYO PHARMA Investigative site 0104
    Gent, 3000, Belgium
  • ENYO PHARMA Investigative site 0103
    Gent, 9000, Belgium
  • ENYO PHARMA Investigative site 0201
    Angers, 49933, France
  • ENYO PHARMA Investigative site
    Créteil, 94010, France
  • ENYO PHARMA Investigative site 0203
    Limoges, 87000, France
  • ENYO PHARMA Investigative site 0204
    Lyon, 69004, France
  • ENYO PHARMA Investigative site 0206
    Paris, 75013, France
  • ENYO PHARMA Investigative site 0202
    Pessac, 33600, France
  • ENYO PHARMA Investigative site 0207
    Toulouse, 31059, France
  • ENYO PHARMA Investigative site 0205
    Villejuif, 94800, France
  • ENYO PHARMA Investigative site 0429
    San Juan, Puerto Rico
  • ENYO PHARMA Investigative site 0304
    Belfast, BT12 6BA, United Kingdom
  • ENYO PHARMA Investigative site 0302
    Cambridge, CB2 0QQ, United Kingdom
  • ENYO PHARMA Investigative site 0303
    London, E1 1BB, United Kingdom
  • ENYO PHARMA Investigative site 0305
    London, SE5 9RS, United Kingdom
  • ENYO PHARMA Investigative site 0301
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol. 2023 Mar;78(3):479-492. doi: 10.1016/j.jhep.2022.10.023. Epub 2022 Nov 9. PubMed 36334688 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jun 2021, 28 months.

Results were first posted in May 2023, 1 year 10 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 28 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 22, 2019
StartActual
Jan 30, 2019
Primary completionActual
Jun 16, 2021
CompletionActual
Jul 6, 2021
Results first posted
May 6, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03812029
Lead sponsor
Enyo Pharma
Responsible party
Sponsor
First posted
Jan 22, 2019
Start date
Jan 30, 2019
Primary completion
Jun 16, 2021
Completion
Jul 6, 2021
Results posted
May 6, 2023
Last update
May 6, 2023

Study contacts

Harrison Stephen, MD
principal investigator · Pinnacle Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion